Axolotl Biologix Acquires Protein Genomics’ Research Lab and Signs License Agreement

0
514

In Arizona, Axolotl Biologix, a regenerative human cell and tissue medical technologies company, entered into an exclusive worldwide license agreement with Protein Genomics, Inc., an R&D company focused on biopolymers for applications in wound healing and tissue regeneration. The license agreement allows Axolotl Biologix to use Protein Genomics’ patents and manufacturing knowledge for a biomimetic skin substitute made from biomaterial called Elastropin. This will help grow and expand Axolotl Biologix’s burn, surgical and wound treatment products. Axolotl Biologix is also acquiring Protein Genomics’ research laboratory in Flagstaff as part of the agreement, and gave a heads up that they plan on filing three new patents in the very near future, so stay tuned.